ILiAD Biotechnologies Overview

  • Founded
  • 2012

Founded
  • Status
  • Private

  • Employees
  • 12

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $23.5M

  • Investors
  • 8

ILiAD Biotechnologies General Information

Description

Developer of a medical vaccine intended to prevent and offer treatment of human disease caused by Bordetella pertussis. The company's vaccine is a live attenuated pertussis vaccine inducing the immune system to produce protective antibodies against B. pertussis infection, enabling patients to recover from whooping cough and other serious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 4581 Weston Road
  • Suite 260
  • Weston, FL 33331
  • United States
+1 (954) 000-0000

ILiAD Biotechnologies Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ILiAD Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 16-Mar-2021 $23.5M 000.00 Completed Clinical Trials - Phase 2
7. Later Stage VC 30-Mar-2020 00.00 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC 19-Dec-2018 000.00 000.00 Completed Clinical Trials - Phase 2
5. Angel (individual) 07-Feb-2018 00000 000.00 Completed Clinical Trials - Phase 1
4. Seed Round 13-Apr-2017 000 000.00 Completed Clinical Trials - Phase 1
3. Angel (individual) 13-Nov-2015 00000 00.000 Completed Clinical Trials - Phase 1
2. Grant $11.1M $3.81M Completed Clinical Trials - Phase 1
1. Angel (individual) $3.81M $3.81M Completed Clinical Trials - Phase 1
To view ILiAD Biotechnologies’s complete valuation and funding history, request access »

ILiAD Biotechnologies Executive Team (7)

Name Title Board Seat Contact Info
Keith Rubin MD Founder, Chief Executive Officer & Board Member
Ken Solovay Chief Operating Officer & Board Member
Luis Rios-Nogales Ph.D Executive Vice President & Chief Development Officer
Jim Ramadei Controller
Cheryl Keech Ph.D Co-Chief Medical Officer & Executive Vice President, Clinical Research
You’re viewing 5 of 7 executive team members. Get the full list »

ILiAD Biotechnologies Board Members (9)

Name Representing Role Since
Ariel Pablos-Mendez MD ILiAD Biotechnologies Board Member 000 0000
Avi Naider Self Board Member 000 0000
Bin Yan Ph.D ILiAD Biotechnologies Board Member 000 0000
Corey Horowitz Network-1 Technologies Board Member 000 0000
Cuong Do Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

ILiAD Biotechnologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ILiAD Biotechnologies Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Knott Partners Management Hedge Fund Minority 000 0000 000000 0
Thylacine Capital Venture Capital Minority 000 0000 000000 0
Endo Investors Venture Capital Minority 000 0000 000000 0
JEMS venture capital Venture Capital Minority 000 0000 000000 0
Network-1 Technologies Corporation Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »